Sotoudeh Mohammadi - School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Mitra Rezaei - Department of Pathology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Fatemeh Shojaeian - School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Mihan Pourabdollah - Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
Leila Mohammadi Ziazi - Department of Pathology, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
Sharareh Seifi - Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
Atousa Doroodinia - Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
Babak Salimi - Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
Adnan Khosravi - Tobacco Prevention and Control Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Mohammad Amin Farhangnasab - School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Background & Objective: Various studies showed the use  of epidermal growth factor receptors (EGFRs) gene mutations in the therapeutic plan of patients with advanced lung cancer. This study aimed to investigate the frequency and types of EGFR gene mutations among Iranian patients with lung adenocarcinoma referred to a specialized lung diseases hospital from ۲۰۱۴ to ۲۰۱۹.Methods: The data of all patients with lung adenocarcinoma referred to the Molecular Department of Masih Daneshvari Hospital Laboratory (National Research Institute of Tuberculosis and Lung Diseases) from ۲۰۱۴ to ۲۰۱۹ for EGFR mutation tests were collected. Patients' characteristics data and information on  the frequency and types of EGFR gene mutations were obtained from the hospital information system (HIS). The collected data were analyzed using SPSS ۲۵.Results: A total of ۵۷۰ individuals (Mean age of ۵۸.۷۴, ۵۱.۶% Male) were included  in the study;  ۱۱۳ out of ۵۷۰ patients  (۱۹.۸%)  were diagnosed with gene mutation. In terms of the type of mutation, ۶۵ participants (۵۷%) showed  deletion, ۴۸ patients (۴۲.۱%) were diagnosed with replacement, and one (۰.۹%) case demonstrated  both. Notably, the mutation rate detected among the female patients  was significantly higher than the male ones (P=۰.۰۰۱); in particular, deletion type of mutation was found more among women, although both genders were the same in terms of the replacement frequency. However, the age had no effect on the   mutation in this study (P=۰.۰۵).Conclusion: Among Iranian patients with lung adenocarcinoma, ۱۹.۸% harbored  EGFR gene mutation. This mutation was found in association with lung cancer and could affect the patient's therapeutic plan.

Adenocarcinoma, EGFR Mutation, Frequency, Iranian population, Lung cancer, Smoking